{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:11:53Z","timestamp":1778562713273,"version":"3.51.4"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eribulin is a microtubule inhibitor indicated for metastatic breast cancer (MBC). Previous studies have demonstrated its overall survival benefit in patients with MBC, but data on its efficacy in those with liver metastases are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed the efficacy and safety of eribulin in 73 patients with liver metastases from breast cancer treated at the First Affiliated Hospital of Zhengzhou University between 2020 and 2024. Systemic progression-free survival and objective response rate were assessed per RECIST version 1.1, and adverse events were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median progression-free survival was 3.7 months (95% CI: 2.8\u20134.6), with a systemic objective response rate of 15.1% (95% CI: 7.8%\u201325.4%; partial responses only). The highest objective response rate (21.2%) was numerically observed in the HR+\/HER2\u2212 subtype. The most common adverse events were neutropenia (42.5%), fatigue (37.0%), alopecia (34.2%), and peripheral neuropathy (28.8%), with no treatment-related deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this single-center retrospective exploratory analysis, eribulin-based therapy demonstrated preliminary activity in heavily pre-treated breast cancer patients with liver metastases. These hypothesis-generating findings warrant further prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1795498","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:29:36Z","timestamp":1778560176000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of eribulin therapy for breast cancer with liver metastasis: a retrospective real-world study"],"prefix":"10.3389","volume":"16","author":[{"given":"Zishuo","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengwei","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03502-3","article-title":"Global patterns and trends in breast cancer incidence and mortality across 185 countries","volume":"31","author":"Kim","year":"2025","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-021-10080-4","article-title":"Breast cancer liver metastasis: Current and future treatment approaches","volume":"38","author":"Rashid","year":"2021","journal-title":"Clin Exp Metastasis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.Epi-18-0591","article-title":"A population-based study on liver metastases in women with newly diagnosed breast cancer","volume":"28","author":"Xie","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12885-021-07968-5","article-title":"Risk and prognostic factors of breast cancer with liver metastases","volume":"21","author":"Ji","year":"2021","journal-title":"BMC Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601038","article-title":"Prognostic factors for patients with hepatic metastases from breast cancer","volume":"89","author":"Wyld","year":"2003","journal-title":"Br J Cancer"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/medicines8110061","article-title":"Clinical outcome of patients submitted to liver resection in the context of metastatic breast cancer: A study of a tertiary hospital center","volume":"8","author":"Nogueiro","year":"2021","journal-title":"Medicines (Basel)"},{"key":"B9","first-page":"297","article-title":"Management of liver dominant metastatic breast cancer: Surgery, chemotherapy, or hepatic arterial therapy - benefits and limitations","volume":"67","author":"Rodes Brown","year":"2012","journal-title":"Minerva Chir"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1021\/bi901810u","article-title":"Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability","volume":"49","author":"Smith","year":"2010","journal-title":"Biochemistry"},{"key":"B11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.bbrc.2021.07.033","article-title":"Eribulin induces tumor vascular remodeling through intussusceptive angiogenesis in a sarcoma xenograft model","volume":"570","author":"Taguchi","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2004.08.069","article-title":"In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B","volume":"61","author":"Towle","year":"2001","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12488","article-title":"Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models","volume":"105","author":"Funahashi","year":"2014","journal-title":"Cancer Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.80","article-title":"Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states","volume":"110","author":"Yoshida","year":"2014","journal-title":"Br J Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1200\/jco.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1835853","article-title":"Systematic review of real-world effectiveness of eribulin for locally advanced or metastatic breast cancer","volume":"36","author":"Chabot","year":"2020","journal-title":"Curr Med Res Opin"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1608946","article-title":"The safety of eribulin for the treatment of metastatic breast cancer","volume":"18","author":"Perez-Garcia","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1313610","article-title":"Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: A single-centre retrospective study","volume":"12","author":"Huang","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-07080-1","article-title":"Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-kinase inhibitor treatment for metastatic breast cancer","volume":"205","author":"Goyal","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000489063","article-title":"Eribulin in heavily pretreated metastatic breast cancer patients in the real world: A retrospective study","author":"Pedersini","year":"2018","journal-title":"Oncology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3892\/ol.2020.11948","article-title":"Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single-center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database","volume":"20","author":"Yang","year":"2020","journal-title":"Oncol Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2025.102800","article-title":"Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study","volume":"96","author":"Passildas","year":"2025","journal-title":"Cancer Epidemiol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1795498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T04:29:37Z","timestamp":1778560177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1795498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1795498"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1795498","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"article-number":"1795498"}}